Osagie Imasogie has served on the board of directors for FS KKR Capital Corp. (“FSK”) since 2018, and serves on the boards of trustees for KKR FS Income Trust and KKR FS Income Trust Select.

Mr. Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a Co-Founder and the senior managing partner of PIPV Capital, a private equity firm focused on the life sciences vertical.

Prior to co-founding PIPV Capital, Mr. Imasogie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. Mr. Imasogie has held senior commercial and R&D positions within pharmaceutical companies such as GSK, SmithKline, DuPont Merck and Endo, where he was the founding General Counsel and Senior Vice President for Corporate Development. He has also been a Price Waterhouse corporate finance partner as well as a practicing attorney with a leading U.S. law firm.

Mr. Imasogie is a serial entrepreneur and investor. He was the Founder and Chairman of Iroko Pharmaceuticals, Ception Therapeutics Inc. and Trigenesis Therapeutics Inc. In addition, he serves on the board of a number of financial institutions including Haverford Trust and StoneRidge Investment and is the non-executive Chairman of Quoin Capital. He is also an advisor to Brown Advisory.

He is a Trustee of the University of Pennsylvania and a member of the Board of Advisors of the University of Pennsylvania Law School, where he is an adjunct professor of Law. He also serves on the board of the Philadelphia Orchestra and the Philadelphia Museum of Art.

Mr. Imasogie was also a member of the board of directors of FS KKR Capital Corp. II until its merger with FSK in June 2021.

He holds postgraduate degrees from the University of Pennsylvania Law School and the London School of Economics.